Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Non Operating Income: 2019-2025

Historic Non Operating Income for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to $6.7 million.

  • Keros Therapeutics' Non Operating Income rose 17.17% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year increase of 22.69%. This contributed to the annual value of $23.8 million for FY2024, which is 40.30% up from last year.
  • Keros Therapeutics' Non Operating Income amounted to $6.7 million in Q3 2025, which was down 3.17% from $6.9 million recorded in Q2 2025.
  • Keros Therapeutics' Non Operating Income's 5-year high stood at $7.5 million during Q4 2024, with a 5-year trough of -$138,000 in Q3 2021.
  • Its 3-year average for Non Operating Income is $5.5 million, with a median of $5.7 million in 2024.
  • Per our database at Business Quant, Keros Therapeutics' Non Operating Income plummeted by 151.27% in 2021 and then soared by 5,208.33% in 2023.
  • Over the past 5 years, Keros Therapeutics' Non Operating Income (Quarterly) stood at -$98,000 in 2021, then soared by 2,387.76% to $2.2 million in 2022, then spiked by 177.07% to $6.2 million in 2023, then rose by 21.18% to $7.5 million in 2024, then grew by 17.17% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $6.9 million for Q2 2025, and $6.5 million during Q1 2025.